

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. – 18. (Canceled)

19. (Currently Amended) A method~~Method~~ for diagnosis or~~and~~ therapy of tumours or~~a~~ and diseases characterized by vascular proliferation disease in a patient comprises administering an antibody with specific, high affinity for the ED-B domain of fibronectin having a VH domain with the following amino acid sequence:

VH domain (SEQ ID NO: 30)

<u>E V Q L L E S G G G</u>	<u>L V Q P G G S L R L</u>	<u>S C A A S G F T F S</u>
<u>S F S M S W V R Q A</u>	<u>P G K G L E W V S S</u>	<u>I S G S S G T T Y Y</u>
<u>A D S V K G R F T I</u>	<u>S R D N S K N T L Y</u>	<u>L Q M N S L R A E D</u>
<u>T A V Y Y C A K P F</u>	<u>P Y F D Y W G Q G T</u>	<u>L V T V S S</u>

and having a VL domain with the amino acid sequence encoded by the VL domain encoding DNA of the DNA insert of ATCC deposit no. PTA-9529, wherein an antibody with specific affinity for a characteristic epitope of the ED-B domain of fibronectin, said antibody having improved affinity to said ED-B domain, is used.

20. (Currently Amended) A conjugate~~Conjugate~~ comprising (a) an antibody with specific, high affinity for the ED-B domain of fibronectin having a VH domain with the following amino acid sequence:

VH domain (SEQ ID NO: 30)

<u>E V Q L L E S G G G</u>	<u>L V Q P G G S L R L</u>	<u>S C A A S G F T F S</u>
<u>S F S M S W V R Q A</u>	<u>P G K G L E W V S S</u>	<u>I S G S S G T T Y Y</u>

<u>A D S V K G R F T I</u>	<u>S R D N S K N T L Y</u>	<u>L Q M N S L R A E D</u>
<u>T A V Y Y C A K P F</u>	<u>P Y F D Y W G Q G T</u>	<u>L V T V S S</u>

and having a VL domain with the amino acid sequence encoded by the VL domain encoding DNA of the DNA insert of ATCC deposit no. PTA-9529; an antibody according to claim 1 and (b) a molecule capable of inducing blood coagulation and blood vessel occlusion.

21. (Currently Amended) A conjugateConjugates according to claim 20 wherein the molecule capable of inducing blood coagulation and blood vessel occlusion is a photoactive molecule.

22. (Currently Amended) A conjugateConjugates according to claim 21 wherein the photoactive molecule is a photosensitizer.

23. (Currently Amended) A conjugateConjugates according to claim 22 wherein the photosensitizer absorbs at a wavelength above 600 nm.

24. (Currently Amended) A conjugateConjugates according to claim 22 wherein the photosensitiser is a derivative of tin (IV) chlorine e6.

25. (Currently Amended) A conjugateConjugates according to claim 20 wherein the molecule capable of inducing blood coagulation and blood vessel occlusion is a radionuclide.

26. (Currently Amended) A conjugateConjugates according to claim 25 wherein the radionuclide is an α- or β- emitting radionuclide.

27. (Canceled)

28. (Currently Amended) A conjugateConjugates according to claim 20 comprising a

wherein the molecule capable of inducing blood coagulation and blood vessel occlusion which is represented by a photosensitizer and a molecule which is a radionuclide.

29. (Currently Amended) A method**Method** for the treatment of an angiogenesis-related pathology in a patient comprising administering pathologies wherein a conjugate according to claim 20 is injected.

30. (Currently Amended) A method**Method** for the treatment of an angiogenesis-related pathology in a patient comprising administering pathologies wherein a conjugate according to claim 22 by injectionis injected, followed by irradiating said patientirradiation.

31. (Currently Amended) A method**Method** according to claim 30 wherein the angiogenesis-related pathology treated is caused by or associated with ocular angiogenesis.

32. (Currently Amended) A method**Method** for the treatment of an angiogenesis-related pathology comprising administering pathologies wherein a radionuclide-containing conjugate according to claim 25 by injectionis injected.

33. (Currently Amended) A method**Method** according to claim 32 wherein the radionuclide is astatine-211.

34. (Currently Amended) A method**Method** for the treatment of an angiogenesis-related pathology comprising administering pathologies wherein a conjugate according to claim 28 by injectionis injected.

35. (Canceled)

36. (New) A conjugate of claim 20 wherein the antibody further comprises a linking sequence with the amino acid sequence encoded by the linker-encoding DNA of the DNA insert

of ATCC deposited no. PTA-9529.

37. (New) A conjugate of claim 36 wherein the antibody is radiolabeled.

38. (New) A conjugate of claim 37 wherein the antibody is radioiodinated.

39. (New) A conjugate of claim 36 wherein the antibody is an ScFv antibody.

40. (New) A conjugate of claim 39 wherein the antibody is produced recombinantly.

41. (New) A conjugate of claim 36 wherein the ED-B domain of fibronectin is a human ED-B domain.

42. (New) A conjugate of claim 36 wherein the antibody is monoclonal.

43. (New) A diagnostic kit comprising a conjugate of claim 37 and one or more reagents for detecting angiogenesis.

44. (New) A conjugate comprising (a) an scFv antibody with specific, high affinity for the ED-B domain of fibronectin having VH, VL and linker domains with the amino acid sequences encoded, respectively, by the VH-, VL- and linker-DNA of the DNA insert of ATCC deposit no. PTA-9529 and (b) a molecule capable of inducing blood coagulation and blood vessel occlusion.

45. (New) A conjugate comprising (a) an antibody with specific, high affinity for the ED-B domain of fibronectin and having a VH domain linked to a VL domain, wherein said VH domain has the following amino acid sequence:

VH domain (SEQ ID NO: 30)

E V Q L L E S G G G        L V Q P G G S L R L        S C A A S G F T F S

S F S M S W V R Q A	P G K G L E W V S S	I S G S S G T T Y Y
A D S V K G R F T I	S R D N S K N T L Y	L Q M N S L R A E D
T A V Y Y C A K P F	P Y F D Y W G Q G T	L V T V S S,

and (b) a molecule capable of inducing blood coagulation and blood vessel occlusion